(P057) Acute-Phase Response Before Treatment Predicts Radiation Esophagitis in Non–Small-Cell Lung Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Radiation esophagitis (RE) represents an inflammatory reaction to radiation therapy (RT). We hypothesized that aspects of the physiologic acute-phase response (APR), specifically increased platelet and decreased hemoglobin levels, predict RE.

Chad Tang, MD, Zhongxing Liao, MD, Yan Zhuang, MD, Lawrence Levy, MS, Chun Hung, BS, Xiaodong Li, MD, Shane Krafft, MS, Mary Martel, PhD, Daniel Gomez, MD, Ritsuko Komaki, MD; UT MD Anderson Cancer Center

Background and Purpose: Radiation esophagitis (RE) represents an inflammatory reaction to radiation therapy (RT). We hypothesized that aspects of the physiologic acute-phase response (APR), specifically increased platelet and decreased hemoglobin levels, predict RE.

Materials and Methods: We retrospectively analyzed 285 patients with non–small-cell lung cancer treated with definitive radiation. The primary analysis was the association of pre-RT lab values with symptomatic (grade ≥ 2) RE. Univariate and stepwise multivariate odds ratios (ORs) were calculated to test associations of clinical and pretreatment lab values with RE. Optimal cutpoints for individual variables and multivariable RE risk stratification groupings were determined via recursive portioning analysis (RPA).

Results: Pretreatment platelet counts were higher and hemoglobin levels were lower in patients who developed RE (P < .05), findings consistent with the APR. Based on these two pretreatment risk factors-high platelets and low hemoglobin-an APR score was defined as 0 (no risk factors), 1 (either risk factor), or 2 (both risk factors). A 1-point increase in APR score was significantly associated with RE in both univariate (OR = 2.3; P = .001) and multivariate (OR = 2.1; P = .002) analyses. Other variables identified on multivariate analysis to be significantly associated with RE include concurrent chemotherapy use (OR = 2.5; P = .008), in addition to mean (OR = 2.3; P = .0004) and max (OR = 2.4; P = .009) esophageal doses. RPA-based RE risk stratification produced three risk groups based on APR score, chemotherapy use, and dosimetric parameters.

Conclusions: Patients exhibiting aspects of the APR prior to RT initiation were more prone to RE development. The APR score may represent a novel metric to predict for RE. We propose a multivariate algorithm incorporating this score.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content